Jeon Jong Ik

Dr. Jeon Jong Ik

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Food Science and Biotechnology
Verified
Journal Article
Open access
PDF file
Seockmo KuSeockmo Ku
Seockmo Ku
Md Ariful HaqueMd Ariful Haque
Md Ariful Haque
MJMin Ji Jang
Min Ji Jang
Jaehyun AhnJaehyun Ahn
Jaehyun Ahn
DCDeokyeong Choe
Deokyeong Choe
MPMyeong Soo Park
Myeong Soo Park
This review explores the role and health impacts of probiotics, focusing specifically on Bifidobacterium spp. It highlights the functionalities that Bifidobacteria can provide, underscored by the historical evolution of definitions and technological advancements related to probiotics. By examining the association between Bifidobacteria and longevity, this review suggests new avenues for health enhancement. Highlighting case studies of centenarians, it presents examples related to human aging, illuminating the potential links to longevity through research on Bifidobacterium strains found in centenarians. This review not only emphasizes the importance of current research but also advocates for further investigation into the health benefits of Bifidobacteria, underlining the necessity for continuous study in the nutraceutical field.

1 November 2019 in Infection and Immunity
Verified
Journal Article
Closed access
JIJeon Jong Ik
Jeon Jong Ik
Su Hyuk KoSu Hyuk Ko
Su Hyuk Ko
Jung Mogg KimJung Mogg Kim
Jung Mogg Kim
The Bacteroides fragilis enterotoxin (BFT), a virulence factor of enterotoxigenic B. fragilis (ETBF), interacts with intestinal epithelial cells and can provoke signals that induce mucosal inflammation. Although β-catenin signaling is reported to be associated with inflammatory responses and BFT is known to cleave E-cadherin linked with β-catenin, little is known about the β-catenin-mediated regulation of inflammation in ETBF infection.

21 August 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
MSMinKyung Sung
MinKyung Sung
SSSeongrok Sim
Seongrok Sim
ALAhyoung Lim
Ahyoung Lim
JMJin Seok Moon
Jin Seok Moon
JIJeon Jong Ik
Jeon Jong Ik
SYSeokmin Yoon
Seokmin Yoon
Atopic dermatitis (AD) is a chronic inflammatory disorder with immune imbalance, including elevated IgE levels and mast cell activation mediated by Th2 cytokines, leading to allergic inflammation and impaired skin barrier function. Current treatment limitations highlight the need for safer and more effective AD alternatives. We aimed to evaluate the therapeutic effects of multi-strain probiotics, BCL-2 (comprising Lactiplantibacillus plantarum LRCC5264 and Bifidobacterium longum RAPO), in alleviating AD clinical signs and elucidate its underlying immunomodulatory mechanisms. In vitro, BCL-2 treatment significantly reduced IL-4 secretion in RBL-2H3 cells, with higher inhibitory effects than single-strain treatment. In vivo, BCL-2 (106–108 CFU/day) was orally administered for 28 days to AD-induced Nc/Nga mice. BCL-2 treatment improved the clinical signs and histopathological features of AD, including epidermal hypertrophy, hyperkeratosis, and mast cell infiltration (p < 0.05). It also reduced neutrophil and eosinophil counts and modulated cytokine and chemokine profiles, notably decreasing IL-17, IL-5, IL-6, TNF-α, IL-1β, TARC, and eotaxin, while increasing IL-10, IFN-γ, and IL-12 (p < 0.05). Among the tested concentrations, 107 CFU exhibited the most effective immune modulation with no adverse effects on body weight. These findings demonstrate the therapeutic potential of BCL-2 in AD; however, further studies are required to validate its clinical relevance.

24 September 2025 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Closed access
PDF file
SKSini Kang
Sini Kang
ZPZhihua Peng
Zhihua Peng
RWRu Wei
Ru Wei
JLJiaxin Liu
Jiaxin Liu
HKHee-Jun Kim
Hee-Jun Kim
Seockmo KuSeockmo Ku
Seockmo Ku

31 May 2025 in Food Engineering Progress
Verified
Journal Article
Open access
PDF file
JMJin Seok Moon
Jin Seok Moon
SSSeongrok Sim
Seongrok Sim
JIJeon Jong Ik
Jeon Jong Ik
JPJi Yoon Park
Ji Yoon Park
JKJin-Woo Kim
Jin-Woo Kim
KHKeon Heo
Keon Heo
Maintaining probiotic viability during storage, freeze-drying, and gastrointestinal transit is essential to ensure efficacy. The present study evaluated VitaShield Coating® (VSC), an innovative stabilization technology incorporating vitamins A, C, and E, for enhancing the viability of Bifidobacterium strains. VSC-coated B. bifidum BGN4 exhibited a significantly higher freeze-drying recovery rate (43.91±4.69%) compared to that of the uncoated group (15.31±6.53%, p<0.0001), with scanning electron microscopy (SEM) confirming preservation of structural integrity. Gastrointestinal stability also improved, as coated cells retained 26.21±2.41% viability in simulated gastric fluid, significantly outperforming uncoated cells (3.20±2.30%, p<0.0001). Gas chromatography-mass spectrometry (GC-MS) revealed a significant increase in polyunsaturated fatty acids (PUFAs) in coated cells, indicating enhanced membrane stability. Furthermore, storage stability of four Bifidobacterium strains (AD011, BORI, BGN4, and RAPO) was evaluated over 16 weeks at 25°C and 30°C. The findings indicate that the VSC coating effectively protects probiotic strains under harsh storage conditions, mitigating viability loss over time. Overall, this study showed that the VSC coating serves as a multifunctional stabilization technology that provides mechanical, osmotic, and oxidative stress protection. Its ability to improve probiotic survival under harsh conditions enables its practical and scalable use in formulations and enhances stability.